{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:39:30Z","timestamp":1793410770324,"version":"4.5.0"},"reference-count":96,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>Background: Statins are a cornerstone of therapy to reduce LDL cholesterol and cardiovascular diseases. However, their use may cause adverse events. This umbrella review aims to comprehensively review the safety profile of statin therapy. Methods: PubMed and Embase were searched to identify systematic reviews, scoping reviews, meta-analyses and network meta-analyses on statin safety. Extracted data included study type, data source, number of included studies, search date range, participant numbers, interventions, safety outcomes, results and funding. Risk of bias was assessed using the AMSTAR 2 instrument. Data underwent descriptive statistical analysis. Results: Seventy-two reviews were included, mostly based on clinical trials (70.8%) and observational studies (59.7%). Only 21 (29.2%) reported results for individual statins, with atorvastatin being the most frequently evaluated individual statin (95.2%). Nearly 86% of the reviews were rated as Critically Low in overall confidence. Statins were associated with an increased risk of new-onset diabetes, particularly rosuvastatin and atorvastatin, whereas pitavastatin may be protective. Liver injury\/dysfunction and elevated transaminases were observed, along with a small risk of muscle-related symptoms, specifically at higher statin intensity. Rare serious events, such as necrotising myopathy, were reported. Pregnancy studies indicated an increased risk of spontaneous abortion. Conclusion: Although overall statin safety is favourable, the risks of diabetes, liver dysfunction, enzyme elevations and muscle symptoms require consideration, especially with high-intensity therapy or specific statins. Pitavastatin may be a safer option for patients at metabolic risk. Therapy should be tailored to individual patient factors. Further research is needed to clarify rare or inconsistent outcomes.<\/jats:p>","DOI":"10.15420\/ecr.2026.03","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:58:16Z","timestamp":1784541496000},"source":"Crossref","is-referenced-by-count":1,"title":["Safety Profile of Statins: An Umbrella Review of Systematic Reviews and Meta-analyses"],"prefix":"10.15420","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2061-4718","authenticated-orcid":false,"given":"Ana","family":"Penedones","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04z8k9a98","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Coimbra"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-8717","authenticated-orcid":false,"given":"Diogo","family":"Mendes","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04z8k9a98","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Coimbra"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5025-244X","authenticated-orcid":false,"given":"Andreia Rodrigues","family":"Lopes","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/031xaae12","id-type":"ROR","asserted-by":"publisher"}],"name":"Unidade Local de Sa\u00fade Santa Maria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e2nia","family":"Oliveira","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01c27hj86","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Lisbon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Alves","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04z8k9a98","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Coimbra"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6334-2137","authenticated-orcid":false,"given":"Augusto","family":"Filipe","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01rn5yy33","id-type":"ROR","asserted-by":"publisher"}],"name":"Grupo Tecnimede (Portugal)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Chou R, Cantor A, Dana T, et al. Statin use for the primary prevention of cardiovascular disease in adults: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 2022;328:754\u201371. https:\/\/doi.org\/10.1001\/jama.2022.12138; PMID:\u00a035997724.","DOI":"10.1001\/jama.2022.12138"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Tecson KM, Kluger AY, Cassidy-Bushrow AE, et al. Usefulness of statins as secondary prevention against recurrent and terminal major adverse cardiovascular events. Am J Cardiol 2022;176:37\u201342. https:\/\/doi.org\/10.1016\/j.amjcard.2022.04.018; PMID:\u00a035606173.","DOI":"10.1016\/j.amjcard.2022.04.018"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Yang C, Wu YJ, Qian J, Li JJ. Landscape of statin as a cornerstone in atherosclerotic cardiovascular disease. Rev Cardiovasc Med 2023;24:373. https:\/\/doi.org\/10.31083\/j.rcm2412373; PMID:\u00a039077097.","DOI":"10.31083\/j.rcm2412373"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res 2017;120:229\u201343. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308537; PMID:\u00a028057795.","DOI":"10.1161\/CIRCRESAHA.116.308537"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2019;39:e38\u201381. https:\/\/doi.org\/10.1161\/ATV.0000000000000073; PMID:\u00a030580575.","DOI":"10.1161\/ATV.0000000000000081"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:2532\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(16)31357-5; PMID:\u00a027616593.","DOI":"10.1016\/S0140-6736(16)31357-5"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Averbukh LD, Turshudzhyan A, Wu DC, Wu GY. Statin-induced liver injury patterns: a clinical review. J Clin Transl Hepatol 2022;10:543\u201352. https:\/\/doi.org\/10.14218\/JCTH.2021.00271; PMID:\u00a035836753.","DOI":"10.14218\/JCTH.2021.00271"},{"key":"ref7","unstructured":"National Institute for Health and Care Excellence (NICE). Evidence Review for Statins: Efficacy and Adverse Effects: Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification. London: NICE, 2023."},{"key":"ref8","unstructured":"JBI. JBI manual for evidence synthesis. 2024. https:\/\/jbi-global-wiki.refined.site\/space\/MANUAL (accessed 9 January 2026)."},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Gates M, Gates A, Pieper D, et al. Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement. BMJ 2022;378:e070849. https:\/\/doi.org\/10.1136\/bmj-2022-070849; PMID:\u00a035944924.","DOI":"10.1136\/bmj-2022-070849"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71; PMID:\u00a033782057.","DOI":"10.1136\/bmj.n71"},{"key":"ref11","unstructured":"National Institute for Health and Care Research. PROSPERO: international prospective register of systematic reviews. 2025. https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251185582 (accessed 9 January 2026)."},{"key":"ref12","unstructured":"Clarivate. EndNote 21 Help Guide. 2023. https:\/\/supportcenter.clarivate.com\/s\/article\/EndNote-21-Help-Guide-and-Quick-Reference-Guide?language=en_US (accessed 9 January 2026)."},{"key":"ref13","unstructured":"WHO. ICD-11 for mortality and morbidity statistics. 2025. https:\/\/icd.who.int\/browse\/2025-01\/mms\/en (accessed 9 January 2026)."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ 2017;358:j4008. https:\/\/doi.org\/10.1136\/bmj.j4008; PMID:\u00a028935701.","DOI":"10.1136\/bmj.j4008"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods 2020;12:55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411; PMID:\u00a032336025.","DOI":"10.1002\/jrsm.1411"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Zhang Z, Deng C, Ma X, et al. The association between statin use and osteoarthritis-related outcomes: an updated systematic review and meta-analysis. Front Pharmacol 2022;13:1003370. https:\/\/doi.org\/10.3389\/fphar.2022.1003370; PMID:\u00a036506528.","DOI":"10.3389\/fphar.2022.1003370"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Wang X, Li J, Wang T, et al. Associations between statins and adverse events in secondary prevention of cardiovascular disease: pairwise, network, and dose\u2013response meta-analyses of 47 randomized controlled trials. Front Cardiovasc Med 2022;9:929020. https:\/\/doi.org\/10.3389\/fcvm.2022.929020; PMID:\u00a036093163.","DOI":"10.3389\/fcvm.2022.929020"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Hirsch A, Ternovsky N, Zwas DR, et al. The effect of statins exposure during pregnancy on congenital anomalies and spontaneous abortions: a systematic review and meta-analysis. Front Pharmacol 2022;13:1003060. https:\/\/doi.org\/10.3389\/fphar.2022.1003060; PMID:\u00a036249743.","DOI":"10.3389\/fphar.2022.1003060"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Teoh RJJ, Huang CJ, Chan CP, et al. Does statin increase the risk of intracerebral hemorrhage in stroke survivors? A meta-analysis and trial sequential analysis. Ther Adv Neurol Disord 2019;12:1756286419864830. https:\/\/doi.org\/10.1177\/1756286419864830; PMID:\u00a031384308.","DOI":"10.1177\/1756286419864830"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Wu F, Wang C, Li S, et al. Association between statins administration and influenza susceptibility: a systematic review and meta-analysis of longitudinal studies. Viruses 2024;16:278. https:\/\/doi.org\/10.3390\/v16020278; PMID:\u00a038400053.","DOI":"10.3390\/v16020278"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Fan L, Wang Y, Liu X, Guan X. Association between statin use and herpes zoster: systematic review and meta-analysis. BMJ Open 2019;9:e022897. https:\/\/doi.org\/10.1136\/bmjopen-2018-022897; PMID:\u00a030765397.","DOI":"10.1136\/bmjopen-2018-022897"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Bolt L, Speierer A, B\u00e9trisey S, et al. Is there a shift from cardiovascular to cancer death in lipid-lowering trials? A systematic review and meta-analysis. PLoS One 2024;19:e0297852. https:\/\/doi.org\/10.1371\/journal.pone.0297852; PMID:\u00a038329982.","DOI":"10.1371\/journal.pone.0297852"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Islam MM, Yang HC, Nguyen PA, et al. Exploring association between statin use and breast cancer risk: an updated meta-analysis. Arch Gynecol Obstet 2017;296:1043\u201353. https:\/\/doi.org\/10.1007\/s00404-017-4533-3; PMID:\u00a028940025.","DOI":"10.1007\/s00404-017-4533-3"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Yang K, Marley A, Tang H, et al. Statin use and non-melanoma skin cancer risk: a meta-analysis of randomized controlled trials and observational studies. Oncotarget 2017;8:75411\u20137. https:\/\/doi.org\/10.18632\/oncotarget.20034; PMID:\u00a029088876.","DOI":"10.18632\/oncotarget.20034"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Ponnala V, Narapaka PK, Garapati P, et al. Exploring the association between statin use and the risk of pancreatic cancer: an updated meta-analysis of observational studies. Curr Pharmacol Rep 2023;9:167\u201376. https:\/\/doi.org\/10.1007\/s40495-023-00319-x.","DOI":"10.1007\/s40495-023-00319-x"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Wang D, Dai S, Lou D, et al. Association between statins exposure and risk of skin cancer: an updated meta-analysis. Int J Dermatol 2023;62:1332\u201344. https:\/\/doi.org\/10.1111\/ijd.16816; PMID:\u00a037681467.","DOI":"10.1111\/ijd.16816"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Masson W, Lobo M, Barbagelata L, Nogueira JP. Statins and new-onset diabetes in primary prevention setting: an updated meta-analysis stratified by baseline diabetes risk. Acta Diabetol 2024;61:351\u201360. https:\/\/doi.org\/10.1007\/s00592-023-02205-w; PMID:\u00a037934231.","DOI":"10.1007\/s00592-023-02205-w"},{"key":"ref28","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol 2024;12:306\u201319. https:\/\/doi.org\/10.1016\/S2213-8587(24)00040-8; PMID:\u00a038554713."},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Kamran H, Kupferstein E, Sharma N, et al. Statins and new-onset diabetes in cardiovascular and kidney disease cohorts: a meta-analysis. Cardiorenal Med 2018;8:105\u201312. https:\/\/doi.org\/10.1159\/000485196; PMID:\u00a029617000.","DOI":"10.1159\/000485196"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Casula M, Mozzanica F, Scotti L, et al. Statin use and risk of new-onset diabetes: a meta-analysis of observational studies. Nutr Metab Cardiovasc Dis 2017;27:396\u2013406. https:\/\/doi.org\/10.1016\/j.numecd.2017.03.001; PMID:\u00a028416099.","DOI":"10.1016\/j.numecd.2017.03.001"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Cai T, Abel L, Langford O, et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose\u2013response meta-analyses. BMJ 2021;374:n1537. https:\/\/doi.org\/10.1136\/bmj.n1537; PMID:\u00a034261627.","DOI":"10.1136\/bmj.n1537"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Rahal AJ, ElMallah AI, Poushuju RJ, Itani R. Do statins really cause diabetes? A meta-analysis of major randomized controlled clinical trials. Saudi Med J 2016;37:1051\u201360. https:\/\/doi.org\/10.15537\/smj.2016.10.16078; PMID:\u00a027652354.","DOI":"10.15537\/smj.2016.10.16078"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Thakker D, Nair S, Pagada A, et al. Statin use and the risk of developing diabetes: a network meta-analysis. Pharmacoepidemiol Drug Saf 2016;25:1131\u201349. https:\/\/doi.org\/10.1002\/pds.4020; PMID:\u00a027277934.","DOI":"10.1002\/pds.4020"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Singh H, Kaur S, Kaushal P, et al. Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis. Expert Rev Clin Pharmacol 2024;17:1173\u201381. https:\/\/doi.org\/10.1080\/17512433.2024.2433603; PMID:\u00a039587804.","DOI":"10.1080\/17512433.2024.2433603"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Li W, Wu C, Li W, Li L. LDL-cholesterol lowering agents (statins and PCSK9 inhibitors) and the risk of intracerebral hemorrhage: a network meta-analysis. J Stroke Cerebrovasc Dis 2025;34:108224. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2025.108224; PMID:\u00a039755190.","DOI":"10.1016\/j.jstrokecerebrovasdis.2025.108224"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Li Z, Xu WQ, Wang JQ, et al. The double-edged sword of statins in intracerebral hemorrhage patients: a systematic review and meta-analysis. Front Neurol 2025;16:1519818. https:\/\/doi.org\/10.3389\/fneur.2025.1519818; PMID:\u00a039931549.","DOI":"10.3389\/fneur.2025.1519818"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"B\u00e9trisey S, Haller ML, Efthimiou O, et al. Lipid-lowering therapy and risk of hemorrhagic stroke: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2024;13:e030714. https:\/\/doi.org\/10.1161\/JAHA.123.030714; PMID:\u00a038323514.","DOI":"10.1161\/JAHA.123.030714"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Pandit AK, Kumar P, Kumar A, et al. High-dose statin therapy and risk of intracerebral hemorrhage: a meta-analysis. Acta Neurol Scand 2016;134:22\u20138. https:\/\/doi.org\/10.1111\/ane.12540; PMID:\u00a026647879.","DOI":"10.1111\/ane.12540"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Liu X, Zhu H, Zheng H, et al. Stains therapy and the risk of all bleeding and intracranial hemorrhage: a meta-analysis of randomized controlled studies. J Evid Based Med 2022;15:373\u201384. https:\/\/doi.org\/10.1111\/jebm.12507; PMID:\u00a036510635.","DOI":"10.1111\/jebm.12507"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Ziff OJ, Banerjee G, Ambler G, Werring DJ. Statins and the risk of intracerebral haemorrhage in patients with stroke: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2019;90:75\u201383. https:\/\/doi.org\/10.1136\/jnnp-2018-318483; PMID:\u00a030150320.","DOI":"10.1136\/jnnp-2018-318483"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Somagutta MKR, Shama N, Pormento MKL, et al. Statin-induced necrotizing autoimmune myopathy: a systematic review. Reumatologia 2022;60:63\u20139. https:\/\/doi.org\/10.5114\/reum.2022.114108; PMID:\u00a035645423.","DOI":"10.5114\/reum.2022.114108"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Nazir S, Lohani S, Tachamo N, et al. Statin-associated autoimmune myopathy: a systematic review of 100 cases. J Clin Rheumatol 2017;23:149\u201354. https:\/\/doi.org\/10.1097\/RHU.0000000000000497; PMID:\u00a028277343.","DOI":"10.1097\/RHU.0000000000000497"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Alves C, Mendes D, Batel Marques F. Statins and risk of cataracts: a systematic review and meta-analysis of observational studies. Cardiovasc Ther 2018;36:e12480. https:\/\/doi.org\/10.1111\/1755-5922.12480; PMID:\u00a030597753.","DOI":"10.1111\/1755-5922.12480"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Yu S, Chu Y, Li G, et al. Statin use and the risk of cataracts: a systematic review and meta-analysis. J Am Heart Assoc 2017;6:e004180. https:\/\/doi.org\/10.1161\/JAHA.116.004180; PMID:\u00a028320745.","DOI":"10.1161\/JAHA.116.004180"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Pan SY, Chen YY, Hsu MY, et al. Associations of different types of statins with the risk of open-angle glaucoma: a systematic review and network meta-analysis. Graefes Arch Clin Exp Ophthalmol 2025;263:201\u20138. https:\/\/doi.org\/10.1007\/s00417-024-06620-9; PMID:\u00a039212799.","DOI":"10.1007\/s00417-024-06620-9"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Fakhri M, Nowroozpoor Dailami KN, Ahmadi H, Ramezanpour M. Association between statins administration and glaucoma; a systematic review and meta-analysis of observational studies. J Nephropharmacol 2025;14:e12754. https:\/\/doi.org\/10.34172\/npj.2025.12754.","DOI":"10.34172\/npj.2025.12754"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Liang X, He Q, Zhao Q. Effect of stains on LDL reduction and liver safety: a systematic review and meta-analysis. BioMed Res Int 2018;2018:7092414. https:\/\/doi.org\/10.1155\/2018\/7092414; PMID:\u00a029693013.","DOI":"10.1155\/2018\/7092414"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Tsui L, Wang D, Fan C, et al. Evaluation of statin-induced muscle and liver adverse drug reactions in the Chinese population: a retrospective analysis of clinical trial data from 1992 to 2023. Eur J Hosp Pharm 2025;33:50\u20135. https:\/\/doi.org\/10.1136\/ejhpharm-2024-004352; PMID:\u00a039922684.","DOI":"10.1136\/ejhpharm-2024-004352"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Hou Q, Chen Y, Zhang Y, Pang C. Comparative muscle tolerability of different types and intensities of statins: a network meta-analysis of double-blind randomized controlled trials. Cardiovasc Drugs Ther 2024;38:459\u201369. https:\/\/doi.org\/10.1007\/s10557-022-07405-0; PMID:\u00a036447018.","DOI":"10.1007\/s10557-022-07405-0"},{"key":"ref50","unstructured":"Cholesterol Treatment Trialists\u2019 Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet 2022;400:832\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(22)01545-8; PMID:\u00a036049498."},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Davis JW, Weller SC. Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153\u00a0000 patients. BMJ Open 2021;11:e043714. https:\/\/doi.org\/10.1136\/bmjopen-2020-043714; PMID:\u00a034130955.","DOI":"10.1136\/bmjopen-2020-043714"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Karadas B, Uysal N, Erol H, et al. Pregnancy outcomes following maternal exposure to statins: a systematic review and meta-analysis. Br J Clin Pharmacol 2022;88:3962\u201376. https:\/\/doi.org\/10.1111\/bcp.15423; PMID:\u00a035639354.","DOI":"10.1111\/bcp.15423"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Vahedian-Azimi A, Bianconi V, Makvandi S, et al. A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. Atherosclerosis 2021;336:1\u201311. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.09.010; PMID:\u00a034601188.","DOI":"10.1016\/j.atherosclerosis.2021.09.010"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Vahedian-Azimi A, Makvandi S, Banach M, et al. Fetal toxicity associated with statins: a systematic review and meta-analysis. Atherosclerosis 2021;327:59\u201367. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.05.006; PMID:\u00a034044205.","DOI":"10.1016\/j.atherosclerosis.2021.05.006"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Hammad MA, Abdo MS, Mashaly AM, et al. The statins effects on HbA1c control among diabetic patients: an umbrella review of systematic reviews and meta-analyses of observational studies and clinical trials. Diabetes Metab Syndr 2019;13:2557\u201364. https:\/\/doi.org\/10.1016\/j.dsx.2019.07.005; PMID:\u00a031405676.","DOI":"10.1016\/j.dsx.2019.07.005"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Cui JY, Zhou RR, Han S, et al. Statin therapy on glycemic control in type 2 diabetic patients: a network meta-analysis. J Clin Pharm Ther 2018;43:556\u201370. https:\/\/doi.org\/10.1111\/jcpt.12690; PMID:\u00a029733433.","DOI":"10.1111\/jcpt.12690"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Angelidi AM, Stambolliu E, Adamopoulou KI, Kousoulis AA. Is atorvastatin associated with new onset diabetes or deterioration of glycemic control? Systematic review using data from 1.9 million patients. Int J Endocrinol 2018;2018:8380192. https:\/\/doi.org\/10.1155\/2018\/8380192; PMID:\u00a030425742.","DOI":"10.1155\/2018\/8380192"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Cai R, Yuan Y, Sun J, et al. Statins worsen glycemic control of T2DM in target LDL-c level and LDL-c reduction dependent manners: a meta-analysis. Expert Opin Pharmacother 2016;17:1839\u201349. https:\/\/doi.org\/10.1080\/14656566.2016.1220539; PMID:\u00a027488607.","DOI":"10.1080\/14656566.2016.1220539"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Alvarez-Jimenez L, Morales-Palomo F, Moreno-Caba\u00f1as A, et al. Effects of statin therapy on glycemic control and insulin resistance: a systematic review and meta-analysis. Eur J Pharmacol 2023;947:175672. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175672; PMID:\u00a036965747.","DOI":"10.1016\/j.ejphar.2023.175672"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Villani R, Navarese EP, Cavallone F, et al. Risk of statin-induced hypertransaminasemia: a systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc Innov Qual Outcomes 2019;3:131\u201340. https:\/\/doi.org\/10.1016\/j.mayocpiqo.2019.01.003; PMID:\u00a031193835.","DOI":"10.1016\/j.mayocpiqo.2019.01.003"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Masson W, Lobo M, Masson G, et al. Statin use in patients with elevated serum hepatic transaminases at baseline: a meta-analysis. Nutr Metab Cardiovasc Dis 2021;31:1357\u201364. https:\/\/doi.org\/10.1016\/j.numecd.2021.01.026; PMID:\u00a033715945.","DOI":"10.1016\/j.numecd.2021.01.026"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Masson W, Lobo M, Lavalle-Cobo A, et al. Statins and influenza mortality: systematic review and meta-analysis. Rev Chilena Infectol 2022;39:321\u20139 [in Spanish]. https:\/\/doi.org\/10.4067\/s0716-10182022000200321; PMID:\u00a036156694.","DOI":"10.4067\/s0716-10182022000200321"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Vahedian-Azimi A, Mannarino MR, Shojaie S, et al. The effect of statins on the prevalence and mortality of influenza virus infection: a systematic review and meta-analysis. Arch Med Sci 2022;18:1513\u201324. https:\/\/doi.org\/10.5114\/aoms\/149633; PMID:\u00a036457966.","DOI":"10.5114\/aoms\/149633"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Zuin M, Rigatelli G, L\u2019Erario R, et al. Herpes zoster infection and statins: which implications in clinical practice? Eur J Clin Microbiol Infect Dis 2019;38:93\u20139. https:\/\/doi.org\/10.1007\/s10096-018-3399-z; PMID:\u00a030298219.","DOI":"10.1007\/s10096-018-3399-z"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Tripathi S, Gupta E, Galande S. Statins as anti-tumor agents: a paradigm for repurposed drugs. Cancer Rep (Hoboken) 2024;7:e2078. https:\/\/doi.org\/10.1002\/cnr2.2078; PMID:\u00a038711272.","DOI":"10.1002\/cnr2.2078"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Jiang W, Hu JW, He XR, et al. Statins: a repurposed drug to fight cancer. J Exp Clin Cancer Res 2021;40:241. https:\/\/doi.org\/10.1186\/s13046-021-02041-2; PMID:\u00a034303383.","DOI":"10.1186\/s13046-021-02041-2"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Ahmadi M, Amiri S, Pecic S, et al. Pleiotropic effects of statins: a focus on cancer. Biochim Biophys Acta Mol Basis Dis 2020;1866:165968. https:\/\/doi.org\/10.1016\/j.bbadis.2020.165968; PMID:\u00a032927022.","DOI":"10.1016\/j.bbadis.2020.165968"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Carmena R, Betteridge DJ. Diabetogenic action of statins: mechanisms. Curr Atheroscler Rep 2019;21:23. https:\/\/doi.org\/10.1007\/s11883-019-0780-z; PMID:\u00a031037345.","DOI":"10.1007\/s11883-019-0780-z"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Laakso M, Fernandes Silva L. Statins and risk of type 2 diabetes: mechanism and clinical implications. Front Endocrinol (Lausanne) 2023;14:1239335. https:\/\/doi.org\/10.3389\/fendo.2023.1239335; PMID:\u00a037795366.","DOI":"10.3389\/fendo.2023.1239335"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Arnaboldi L, Corsini A. Could changes in adiponectin drive the effect of statins on the risk of new-onset diabetes? The case of pitavastatin. Atheroscler Suppl 2015;16:1\u201327. https:\/\/doi.org\/10.1016\/S1567-5688(14)70002-9; PMID:\u00a025575403.","DOI":"10.1016\/S1567-5688(14)70002-9"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Jeong HS, Hong SJ, Son S, et al. Incidence of new-onset diabetes with 1 mg versus 4 mg pitavastatin in patients at high risk of developing diabetes during a 3-year follow-up. Cardiovasc Diabetol 2019;18:162. https:\/\/doi.org\/10.1186\/s12933-019-0969-z; PMID:\u00a031752850.","DOI":"10.1186\/s12933-019-0969-z"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Adamson P, Greenwood J. How do statins control neuroinflammation? Inflamm Res 2003;52:399\u2013403. https:\/\/doi.org\/10.1007\/s00011-003-1201-9; PMID:\u00a014520514.","DOI":"10.1007\/s00011-003-1201-9"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Ribe AR, Vestergaard CH, Vestergaard M, et al. Statins and risk of intracerebral hemorrhage in individuals with a history of stroke. Stroke 2020;51:1111\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.119.027301; PMID:\u00a032114928.","DOI":"10.1161\/STROKEAHA.119.027301"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Cui C, Yin Q, Li J. Statins reduce the recurrence of spontaneous intracerebral hemorrhage: a systematic review and meta-analysis. Clin Neurol Neurosurg 2025;249:108723. https:\/\/doi.org\/10.1016\/j.clineuro.2025.108723; PMID:\u00a039787892.","DOI":"10.1016\/j.clineuro.2025.108723"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Sridharan K, Sivaramakrishnan G. Genetic determinants of statin-induced myopathy: a network meta-analysis of observational studies. Curr Rev Clin Exp Pharmacol 2026;21:75\u201391. https:\/\/doi.org\/10.2174\/0127724328356429250315163111; PMID:\u00a040176697.","DOI":"10.2174\/0127724328356429250315163111"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Xiang Q, Zhang XD, Mu GY, et al. Correlation between single-nucleotide polymorphisms and statin-induced myopathy: a mixed-effects model meta-analysis. Eur J Clin Pharmacol 2021;77:569\u201381. https:\/\/doi.org\/10.1007\/s00228-020-03029-1; PMID:\u00a033150478.","DOI":"10.1007\/s00228-020-03029-1"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Liu M, Fan F, Zhang Y, Li J. The association of GATM polymorphism with statin-induced myopathy: a systematic review and meta-analysis. Eur J Clin Pharmacol 2021;77:349\u201357. https:\/\/doi.org\/10.1007\/s00228-020-03019-3; PMID:\u00a033051696.","DOI":"10.1007\/s00228-020-03019-3"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Floyd JS, Bloch KM, Brody JA, et al. Pharmacogenomics of statin-related myopathy: meta-analysis of rare variants from whole-exome sequencing. PLoS One 2019;14:e0218115. https:\/\/doi.org\/10.1371\/journal.pone.0218115; PMID:\u00a031242253.","DOI":"10.1371\/journal.pone.0218115"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Xiang Q, Chen SQ, Ma LY, et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis. Pharmacogenomics J 2018;18:721\u20139. https:\/\/doi.org\/10.1038\/s41397-018-0054-0; PMID:\u00a030250148.","DOI":"10.1038\/s41397-018-0054-0"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Ooi KGJ, Khoo P, Vaclavik V, Watson SL. Statins in ophthalmology. Surv Ophthalmol 2019;64:401\u201332. https:\/\/doi.org\/10.1016\/j.survophthal.2019.01.013; PMID:\u00a030703407.","DOI":"10.1016\/j.survophthal.2019.01.013"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Lymperopoulou C, Kandarakis SA, Tzanaki I, et al. The effect of statins on ocular disorders: a systematic review of randomized controlled trials. Pharmaceuticals (Basel) 2023;16:711. https:\/\/doi.org\/10.3390\/ph16050711; PMID:\u00a037242493.","DOI":"10.3390\/ph16050711"},{"key":"ref82","doi-asserted-by":"crossref","unstructured":"Bj\u00f6rnsson ES. Hepatotoxicity of statins and other lipid-lowering agents. Liver Int 2017;37:173\u20138. https:\/\/doi.org\/10.1111\/liv.13308; PMID:\u00a027860156.","DOI":"10.1111\/liv.13308"},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Zacharia G, Jacob A, Karichery M, Sasidharan A. Impact of statins in the liver: a bane or a boon? Can Liver J 2024;7:490\u20139. https:\/\/doi.org\/10.3138\/canlivj-2023-0028; PMID:\u00a040677525.","DOI":"10.3138\/canlivj-2023-0028"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Vell MS, Loomba R, Krishnan A, et al. Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality. JAMA Netw Open 2023;6:e2320222. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.20222; PMID:\u00a037358849.","DOI":"10.1001\/jamanetworkopen.2023.20222"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"Di Stasi SL, MacLeod TD, Winters JD, Binder-Macleod SA. Effects of statins on skeletal muscle: a perspective for physical therapists. Phys Ther 2010;90:1530\u201342. https:\/\/doi.org\/10.2522\/ptj.20090251; PMID:\u00a020688875.","DOI":"10.2522\/ptj.20090251"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Weninger G, Dridi H, Reiken S, et al. Structural basis for simvastatin-induced skeletal muscle weakness associated with type 1 ryanodine receptor T4709M mutation. J Clin Invest 2025;135:e194490. https:\/\/doi.org\/10.1172\/JCI194490; PMID:\u00a041392983.","DOI":"10.1172\/JCI194490"},{"key":"ref87","doi-asserted-by":"crossref","unstructured":"Zhao L, Li S, Gao Y. Efficacy of statins on renal function in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail 2021;43:718\u201328. https:\/\/doi.org\/10.1080\/0886022X.2021.1915799; PMID:\u00a033926359.","DOI":"10.1080\/0886022X.2021.1915799"},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Esmeijer K, Dekkers OM, de Fijter JW, et al. Effect of different types of statins on kidney function decline and proteinuria: a network meta-analysis. Sci Rep 2019;9:16632. https:\/\/doi.org\/10.1038\/s41598-019-53064-x; PMID:\u00a031719617.","DOI":"10.1038\/s41598-019-53064-x"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Zarek J, Koren G. The fetal safety of statins: a systematic review and meta-analysis. J Obstet Gynaecol Can 2014;36:506\u20139. https:\/\/doi.org\/10.1016\/S1701-2163(15)30565-X; PMID:\u00a024927189.","DOI":"10.1016\/S1701-2163(15)30565-X"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Mauricio R, Khera A. Statin use in pregnancy: is it time for a paradigm shift? Circulation 2022;145:496\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.058983; PMID:\u00a035157518.","DOI":"10.1161\/CIRCULATIONAHA.121.058983"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Svendsen K, Christensen JJ, Igland J, et al. Risk of adverse pregnancy outcomes and impact of statin use in pregnant women with familial hypercholesterolemia. Atherosclerosis 2025;408:120442. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.120442; PMID:\u00a040669098.","DOI":"10.1016\/j.atherosclerosis.2025.120442"},{"key":"ref92","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. Lancet 2026;407:689\u2013703. https:\/\/doi.org\/10.1016\/S0140-6736(25)01578-8; PMID:\u00a041655587."},{"key":"ref93","doi-asserted-by":"crossref","unstructured":"Galicia-Garcia U, Jebari S, Larrea-Sebal A, et al. Statin treatment-induced development of type 2 diabetes: from clinical evidence to mechanistic insights. Int J Mol Sci 2020;21:4725. https:\/\/doi.org\/10.3390\/ijms21134725; PMID:\u00a032630698.","DOI":"10.3390\/ijms21134725"},{"key":"ref94","doi-asserted-by":"crossref","unstructured":"Mykk\u00e4nen AJH, Tarkiainen EK, Taskinen S, et al. Genome-wide association study of atorvastatin pharmacokinetics: associations with SLCO1B1, UGT1A3, and LPP. Clin Pharmacol Ther 2024;115:1428\u201340. https:\/\/doi.org\/10.1002\/cpt.3236; PMID:\u00a038493369.","DOI":"10.1002\/cpt.3236"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565\u201381. https:\/\/doi.org\/10.1016\/j.clpt.2006.09.003; PMID:\u00a017178259.","DOI":"10.1016\/j.clpt.2006.09.003"}],"container-title":["European Cardiology Review"],"original-title":[],"link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2026.03","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:59:01Z","timestamp":1784541541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2026.03"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":96,"URL":"https:\/\/doi.org\/10.15420\/ecr.2026.03","relation":{},"ISSN":["1758-3756","1758-3764"],"issn-type":[{"value":"1758-3756","type":"print"},{"value":"1758-3764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"e42"}}